Ikariaincwas A Global Critical Care Company Known For Its Innovative Therapies And Delivery Systems Aimed At Critically Ill Patientsespecially Infants In Neonatal Intensive Care Unitsnicus In Early 2015Ikaria Was Acquired By Mallinckrodt Pharmaceuticalsenhancing Mallinckrodt S Presence In Respiratory Neonatal Critical Care And Hospital Markets Ikaria Developed The Inomaxasystemwhich Delivers Nitric Oxide To Treat Hypoxic Respiratory Failure In Neonatesthe Company Focused On Critical Care Solutions That Addressed Unmet Needs In Medicineproviding Specialized Therapeutics For Vulnerable Patient Populationsafter The Acquisitionikaria S Operations Became Part Of Mallinckrodt S Specialty Brands Segmentwhich Includes A Range Of Therapies For Critical Careautoimmune Diseasesand Rare Conditionsthe Integration Of Ikaria S Products Has Strengthened Mallinckrodt S Offerings In Neonatal Care And Hospital Support
